BashTheBug reaches one million classifications Philip Fowler, 4th October 20184th October 2018 BashTheBug, a citizen science project I run that is helping us measure how different clinical samples of M. tuberculosis grow in the presence of 14 different antibiotics, reached its first million classifications earlier this week. To read more head over to its blog. The photo mosaic on the left is made up of images sent in by volunteers who’ve all contributed to the success of BashTheBug. Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Related antimicrobial resistance citizen science clinical microbiology tuberculosis
New preprint: Including minor alleles improves fluoroquinolone resistance prediction 10th November 202217th November 2022 Fluoroquinolones are used to treat both normal and drug resistant tuberculosis and therefore being able… Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Read More
antimicrobial resistance New publication: Predicting resistance is (not) futile 21st August 201921st August 2019 Our “First Reactions” article has been published in ACS Central Science. We discuss the paper,… Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Read More
meetings ESM Annual Congress 2025 25th June 20251st July 2025 Several of us attended the 45th Annual Congress of the European Society of Mycobacteriology in… Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Read More